Financial Performance - The company's revenue for Q1 2023 was ¥91,015,564.31, a decrease of 14.24% compared to ¥106,122,346.48 in the same period last year[5] - Net profit attributable to shareholders was ¥9,539,039.25, down 35.38% from ¥14,760,900.08 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 91,015,564.31, a decrease of 14.2% compared to CNY 106,122,346.48 in Q1 2022[21] - Net profit for Q1 2023 was CNY 9,539,039.25, representing a decline of 35.5% from CNY 14,760,900.08 in Q1 2022[22] - Earnings per share for Q1 2023 was CNY 0.12, down from CNY 0.25 in Q1 2022[22] Cash Flow and Liquidity - The net cash flow from operating activities improved by 43.97%, reaching -¥11,127,387.13 compared to -¥19,858,081.72 in the previous year[5] - The cash inflow from operating activities for Q1 2023 was CNY 136,716,036.51, an increase of 37.2% compared to CNY 99,605,205.03 in Q1 2022[24] - The total cash and cash equivalents at the end of Q1 2023 stood at CNY 351,162,151.12, compared to CNY 75,681,974.06 at the end of Q1 2022, reflecting a significant increase[25] - Cash and cash equivalents at the end of the period increased by 364.00% to ¥351,162,151.12, primarily due to the inflow of raised funds[13] - The company received CNY 145,000,000.00 from investment recoveries, a substantial rise from CNY 30,194,780.00 in the previous year[24] Assets and Liabilities - Total assets decreased by 6.95% to ¥825,435,046.15 from ¥887,046,604.86 at the end of the previous year[5] - Total current assets decreased from 616,148,533.06 CNY to 552,265,701.21 CNY[18] - The total liabilities as of the end of Q1 2023 were CNY 34,236,287.51, a significant decrease from CNY 105,386,885.47 at the end of the previous year[22] - Total current liabilities decreased from 103,391,569.38 CNY to 32,256,785.02 CNY[18] Investments and Income - Investment income surged by 2080.98% to ¥810,948.41, mainly due to profits from joint ventures[11] - The company reported an investment income of CNY 810,948.41 in Q1 2023, compared to a loss of CNY 40,936.69 in the previous year[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,144[14] - The largest shareholder, Hong Wei, holds 38.14% of the shares, totaling 30,509,490 shares[14] Expenses - The company experienced a 55.20% increase in sales expenses, totaling ¥7,353,346.58, attributed to enhanced marketing efforts[11] - Total operating costs for Q1 2023 were CNY 82,991,701.42, down 6.5% from CNY 88,840,835.37 in the same period last year[21] - Research and development expenses increased to CNY 3,646,778.89, up from CNY 3,352,232.33 in Q1 2022, indicating a focus on innovation[21] Market Strategy - The company has not reported any new product developments or market expansion strategies in the current quarter[15] - The company aims to enhance market expansion and product development strategies in the upcoming quarters[20]
美农生物(301156) - 2023 Q1 - 季度财报